Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTPW) EBT (2022 - 2025)

Historic EBT for 60 Degrees Pharmaceuticals (SXTPW) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' EBT fell 724.63% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 31.1%. This contributed to the annual value of -$8.0 million for FY2024, which is 10860.91% down from last year.
  • 60 Degrees Pharmaceuticals' EBT amounted to -$2.3 million in Q3 2025, which was down 724.63% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' EBT ranged from a high of $4.2 million in Q3 2023 and a low of -$4.2 million during Q2 2024
  • Its 4-year average for EBT is -$1.6 million, with a median of -$2.0 million in 2023.
  • Per our database at Business Quant, 60 Degrees Pharmaceuticals' EBT soared by 38775.21% in 2023 and then tumbled by 53855.78% in 2025.
  • Quarter analysis of 4 years shows 60 Degrees Pharmaceuticals' EBT stood at -$1.7 million in 2022, then decreased by 22.53% to -$2.0 million in 2023, then dropped by 0.16% to -$2.0 million in 2024, then fell by 13.05% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.9 million during Q1 2025.